{
    "clinical_study": {
        "@rank": "40455", 
        "arm_group": [
            {
                "arm_group_label": "1 Electroconvulsive therapy with medication", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "2 Medication monotherapy", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study will evaluate electroconvulsive therapy (ECT) in patients who have not responded\n      adequately to clozapine."
        }, 
        "brief_title": "Electroconvulsive Therapy in Clozapine Refractory Schizophrenia", 
        "condition": "Schizophrenia", 
        "condition_browse": {
            "mesh_term": "Schizophrenia"
        }, 
        "detailed_description": {
            "textblock": "ECT augmentation of clozapine will be compared to clozapine monotherapy in schizophrenic\n      patients who continue to have psychotic symptoms despite optimal treatment with clozapine."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Receiving at least two 400 mg doses of chlorpromazine equivalents for at least 4\n             weeks (may include newer antipsychotics)\n\n          -  Having substantial psychotic symptoms despite at least 12 weeks of treatment (at\n             least 8 weeks at a consistent dose)"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "64", 
        "firstreceived_date": "July 24, 2002", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00042224", 
            "org_study_id": "R01 MH60390", 
            "secondary_id": "DSIR AT-SO"
        }, 
        "intervention": [
            {
                "arm_group_label": "1 Electroconvulsive therapy with medication", 
                "description": "ECT will be used to augment clozapine in schizophrenic patients who continue to have psychotic symptoms despite optimal treatment with clozapine.", 
                "intervention_name": "Electroconvulsive Therapy (ECT)", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "1 Electroconvulsive therapy with medication", 
                    "2 Medication monotherapy"
                ], 
                "description": "Patients with psychotic symptoms will receive clozapine", 
                "intervention_name": "Clozapine", 
                "intervention_type": "Drug", 
                "other_name": "Clozaril"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Clozapine"
        }, 
        "keyword": "Electroconvulsive Therapy", 
        "lastchanged_date": "October 5, 2010", 
        "location": {
            "facility": {
                "address": {
                    "city": "Glen Oaks", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "11004"
                }, 
                "name": "Zucker Hillside Hospital"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "ECT in Clozapine Refractory Schizophrenia", 
        "overall_official": {
            "affiliation": "New Jersey Medical School", 
            "last_name": "Georgios Petrides, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "Phase 1/Phase 2", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00042224"
        }, 
        "responsible_party": {
            "name_title": "Georgios Petrides, MD", 
            "organization": "New Jersey Medical School"
        }, 
        "source": "National Institute of Mental Health (NIMH)", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "National Institute of Mental Health (NIMH)", 
                "agency_class": "NIH"
            }
        }, 
        "start_date": "December 2000", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "December 2005"
    }, 
    "geocoordinates": {
        "Zucker Hillside Hospital": "40.747 -73.712"
    }
}